BioInvent International and ThromboGenics NV announce that they have agreed to amend their long-standing agreement, which covers the co-development of the novel anti-PlGF monoclonal antibody products TB-403 and THR-317. The
Drug Development Biotech
The financing was led by a group of private investors in Norway and the company will use these funds to advance lead product CyPep-1 into a Phase I clinical trial.
Athera Biotechnologies announces that the the U.S. Food and Drug Administration (FDA) have granted Orphan Drug Designation to the fully human antibody PC-mAb, for the treatment of patients with end
Oslo Cancer Cluster (OCC) is currently involved in a big European collaboration through the cluster-to-cluster project PERMIDES. The project aims to utilize novel IT-solutions to accelerate drug development in biotech companies.
BerGenBio announces that the first patients have been dosed and continue on therapy in a Phase I/II randomised trial evaluating the addition of BerGenBio’s selective, potent and orally bio-available AXL
Idogen announces that the European Patent Office will formally grant a patent application, covering the company’s tolerogenic vaccine technology. The EPO approval strengthens the company’s patent portfolio for the vaccine
AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has accepted the first Biologics License Application (BLA) for durvalumab, a